



PharmAust Rights Issue Reaches Minimum Subscription

12 March 2019 – Perth, Australia: PharmAust Limited (ASX:PAA), a clinical-stage oncology company, is pleased to announce that aggregate subscriptions have reached the Minimum Subscription level in its non-renounceable pro-rata entitlement rights issue (Rights Issue).

The Rights Issue offer period opened on 26 February 2019 and will close at 5pm WST Tuesday 19 March 2019.

Executive Chairman Dr Roger Aston said, "We are delighted to reach the minimum subscription level. These funds underpin the company's current Phase 1 work and also the important Phase 2 canine trial."

All Directors are taking up their Rights Issue entitlements in full.

The Company will advise on the final level of subscriptions after close of the Rights Issue on 19 March.

Lead Manager Alto Capital has been engaged by the Company to place any shortfall.

Enquiries:

Dr Roger Aston
Executive Chairman and CEO
Tel: 0402 762 204
rogeraston@pharmaust.com

Robert Bishop
Director
Tel: 0417 445 180
robertbishop@pharmaust.com

About PharmAust (PAA):

PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epi chem, a highly successful contract medicinal chemistry company which generated ~Aus\$3.02m in revenues in the 2018 FY.